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The first endothelium-derived relaxing factor (EDRF) ever
identified is a gasotransmitter, nitric oxide (NO). Recent
studies have provided several lines of evidence to support
the premise that hydrogen sulfide (H2S), another
gasotransmitter, is a new EDRF. H2S production is catalyzed
in mammalian cells by cystathionine b-synthase (CBS) and/or
cystathionine c-lyase (CSE). The expression of CSE proteins
and the activity of CBS have been observed in vascular
endothelial cells. A measurable amount of H2S is produced
from endothelium upon muscarinic cholinergic stimulation.
The endothelium-dependent vasorelaxation induced by H2S
shares many common mechanistic traits with those of
endothelium-derived hyperpolarizing factor (EDHF).
Deficiency in CSE expression increases blood pressure in CSE
knockout mice and significantly diminishes endothelium-
dependent relaxation of resistance arteries. More extensive
and mechanistic studies in the future will help to determine
whether H2S is a new EDRF or the very EDHF.
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Dilation of blood vessels can be regulated by a group of
labile humoral substances released from the endothelium,
namely endothelium-derived relaxing factors (EDRFs). The
paradigm-shaking discovery of nitric oxide (NO) as an
EDRF decades ago1 marked the beginning of a new era in
cardiovascular research. Upon activation by different stimuli,
such as acetylcholine and bradykinin, endothelial cells have
their intracellular calcium level increased, which subsequently
activates the endothelial NO synthase (eNOS). This leads to
the production of NO and citrulline from the substrates
L-arginine and molecular O2. NO is released from endothelial
cells and stimulates guanylyl cyclase in vascular smooth
muscle cells (SMCs). Consequently, cGMP levels in vascular
SMCs are elevated and the cells relax (Figure 1).
The initial excitement of NO discovery has transformed
into many new explorations and triggered wave after wave of
aftershocks. It is generally agreed upon that there are more
than one EDRF, which are produced by the endothelium and
cause blood vessel dilation. Prostacyclin (PGI2) is produced
from the endothelium through cyclooxygenase-1, and binds
to specific receptors in SMCs and activates adenylate cyclase.
Thus, increased cAMP levels in SMCs relax the cells
(Figure 1). In most cases, NO-mediated endothelium-depen-
dent vasorelaxation occurs in large conduit arteries whereas the
endothelium-dependent relaxation of peripheral resistance
arteries does not depend on NO production. After eliminating
the endothelial production of NO and PGI2 by knocking out
the expression of eNOS and cyclooxygenase-1, there is still
residual endothelium-dependent relaxation.2 Even considering
only non-prostanoid EDRF, NO may not be alone. The long-
standing mystery surrounding the endothelium-derived hyper-
polarizing factor (EDHF) has not been solved, and the roles of
other gasotransmitters3 in endothelium-dependent vasorelaxa-
tion have been questioned in recent years.
The chemical profile of hydrogen sulfide (H2S) is similar to
that of NO. Both are small molecules of gas, generated in
mammalian cells by enzymatic catalyzation, and freely permeable
to lipid bilayer. H2S has been traditionally viewed as a toxic gas,
and is infamous for its of ‘rotten egg’ smell. Its toxicological
effect is mainly manifested as acute intoxication and loss of
central respiratory drive. Only in the last decade, biological and
physiological importance of this gas molecule has been exposed
under limelight. In mammalian cells, H2S is produced from
L-cysteine, catalyzed by one of two pyridoxal-50-phosphate-
dependent enzymes, cystathionine b-synthase (CBS) and/or
cystathionine g-lyase (CSE).3 In addition to H2S, L-cysteine
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catabolism also generates ammonium and pyruvate (Figure 2).
The expressions of CBS and CSE are tissue-type specific. CBS
is reported to be the predominant H2S-generating enzyme in the
brain and nervous system and CSE is the predominant
H2S-generating enzyme in pancreatic b-islets, different vascular
tissues, and the heart.3 Physiological range of H2S in circulation
is 10–100mM in fish, rats, and human. Endogenous level of H2S
in brain tissue is approximately 50–160mM.
Our knowledge on the cardiovascular effects of H2S has
amounted in recent years, and the momentum in searching
the physiological and pathophysiological roles of H2S has
been built up. H2S induces relaxation of different vascular
tissues (for example, rat aorta and mesenteric arteries), and
protects the heart from ischemia/reperfusion damage. H2S
can induce vasorelaxation by directly opening KATP channels
in vascular SMCs. KATP channel blocker, glibenclamide,
inhibited H2S-induced dilation of aorta,
4 mesenteric
artery beds,5 or hepatic microcirculation6 and abolished
H2S-evoked blood pressure decrease in vivo.
4 Using the
whole-cell and single-channel patch-clamp technique, direct
evidence was obtained that exogenous H2S activated KATP
channels and hyperpolarized cell membrane of rat aorta and
mesenteric artery SMCs.4 Glibenclamide also abolished H2S-
facilitated carotid sinus baroreflex.7 Inhibition of endogenous
H2S production with D,L-propargylglycine, a membrane
permeable and irreversible inhibitor of CSE, reduced whole-
cell KATP currents.
4 In myocardium, a mitochondrial KATP
channel blocker (5-hydroxydecanoate) or a plasma membrane
KATP channel blocker (glibenclamide) abolished H2S-offered
cardioprotection against myocardiac infarction damage.8
With a broader concept to encompass the origination
from endothelium and downstream target of SMCs, we have
more than one EDRF. Certainly, EDHF can be categorized
into the EDRF class and the idea of H2S being a new EDRF is
both intriguing and appealing.
LINES OF EVIDENCE SUPPORT THE IDENTIFICATION OF H2S
AS AN EDRF
Endothelium production of H2S
Elucidation of the source of H2S production in the blood
vessel wall and the physiological role of this gas in regulating
cardiovascular function may pave the way for new thera-
peutic approach, either pharmacologically or genetically, to
treat and prevent many different cardiovascular diseases,
including hypertension and heart damage. In an earlier study,
CSE mRNA expression was detected in smooth muscles of rat
aorta wall, using an in situ hybridization method.4 In
cultured rat aortic endothelial cells, CSE mRNA was not
detected using reverse transcription-PCR.4 CSE protein
expression was not conducted at that time due to the lack
of CSE-specific antibody.4 In the liver, CSE was found in
hepatocytes and hepatic stellate cells, but not in sinusoidal
endothelial cells.6 It appeared that the vascular endothelium
per se was not equipped with H2S-generating enzymes. This
notion has been recently challenged and it no longer holds
true. CSE protein has been detected in cultured bovine aortic
endothelial cells and human umbilical vein endothelial cells.
Yang et al.9 provided immunohistological evidence for a
predominant localization of CSE protein in the endothelial
layer of vascular tissues of wild-type mice. This newly defined
Agonists
Calmodulin/Ca Calmodulin/Ca
NOS CSE
NO L-arginine
Endothelial cells
Phospholipid or
diacylglycerol
COX-1
H2S L-cysteine AA PG12
cAMP ATP
sGC
GTP cGMP
?
EDHF KCa channel
KATP channel
AC
Smooth muscle
cells
Relaxation
Figure 1 |Molecular basis for endothelium-dependent
vasorelaxation. With different substrates, NO, H2S, and PGI2 are
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Figure 2 | Endogenous synthesis of hydrogen sulfide in
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endothelial localization of CSE can be largely ascribed to the
availability of newly developed selective and specific anti-CSE
antibody. Direct evidence for the endothelium production of
H2S was also obtained. Cultured vascular endothelial cells
produce measurable H2S and silencing CSE in these cells
significantly decreases H2S production.
9
Physiological stimulus for endothelial H2S production
Similar to NO, acute production of H2S from vascular
endothelial cells is triggered by muscarinic cholinergic
activation. Methacholine, a cholinergic receptor agonist,
increased H2S levels in cultured endothelial cells by more
than twofold. Atropine, a cholinergic antagonist, abolished
methacholine effect. In the presence of the calcium
ionophore A23187, endothelial production of H2S is
significantly increased. Chelating of intracellular-free calcium
with BAPTA abolished the effect of A23187 on H2S
production as well as lowering the basal level of H2S in
endothelial cells. Furthermore, co-immunoprecipitation
study demonstrated the binding of calmodulin to recombi-
nant CSE in vitro. This binding is contingent on the presence
of calcium, and abolished by calmodulin antagonist W7.
These results demonstrated that a calcium–calmodulin
system is the prerequisite for muscarinic activation of CSE
in endothelial cells. Once CSE is knocked down from
endothelial cells, the effects of methacholine and A23187 on
H2S production were abolished, indicating CSE activation is the
key link in calcium–calmodulin-dependent H2S production.
9
Endothelium-dependent vasorelaxation induced by H2S
The vasorelaxant effect of H2S is also endothelium-depen-
dent. The removal of endothelium attenuated the relaxation
of rat aortic tissues induced by H2S and shifted H2S
concentration–response curve to the right with EC50 changed
from 136 to 273 mM.10 Although this observation did not
address whether H2S is endothelium derived or not, it shows
that the presence of an intact endothelium does affect H2S-
induced vasorelaxation. The endothelium dependence of H2S
effect was more pronounced in isolated and perfused rat
mesenteric artery bed.5 The removal of the functional
endothelium significantly reduced H2S-induced relaxation
of rat mesenteric artery bed by about sevenfold with EC50 of
H2S changed from 25 to 161 mM (Po0.05). This tissue type-
selective endothelium-dependent effect of H2S is similar to
that of EDHF. The EC50 of H2S in inducing vasorelaxation is
quite close to the reported endogenous level of H2S in
plasma, which suggests that under physiological in vivo
conditions the vascular tone of resistance arteries is likely
regulated by endogenous H2S. Long-term effect of H2S on the
endothelium is observed as the increased proliferation of
vascular endothelial cells, although H2S inhibits proliferation
of many types of cells, such as vascular SMCs.11 NaHS
(10–20 mM), an H2S donor, increased cell growth, migration,
scratched wound healing, and tube-like structure formation
in cultured human umbilical vein endothelial cells. These
effects of NaHS were mediated by PI3K activation and Akt
phosphorylation. Furthermore, NaHS treatment (10 and
50 mmol/kg/day, intraperitoneally) of mice significantly
promoted neovascularization in vivo.12 Deficiency in the
expression of CSE significantly lowers the H2S level in
cardiovascular tissues, especially in endothelial cells. Metha-
choline-induced endothelium-dependent relaxation of resis-
tance mesenteric arteries was significantly diminished in
CSE-deficient mice.9
Stability and removal of H2S
The half-life of NO in blood is counted in seconds and it can
be scavenged by oxyhemoglobin. H2S seems to be more stable
in protein-free solution.13 However, H2S can also be
scavenged by methemoglobin or disulfide-containing mole-
cules such as oxidized glutathione.3 Therefore, the half-life of
free H2S in blood may also be short.
THE EDHF RESEMBLANCE OF H2S
The unique property of EDHF, different from other putative
EDRFs, is its specific action of hyperpolarizing vascular SMCs
so as to close voltage-dependent calcium channels. The effect of
EDHF is mainly mediated by small-conductance KCa channels
and aided by intermediate-conductance KCa channels, which
can be blocked by the co-application of apamin and
charybdotoxin. It has been debated, and the case has not yet
been settled, whether EDHF is a diffusible EDRF or a simple
electrotonic phenomenon that relays membrane potential
change in endothelium to the underneath SMCs through
low-electrical resistance myoendothelial gap junctions. Among
diffusible chemical candidates for EDHF are Kþ ions,
endothelium-derived C-type natriuretic peptide, H2O2, and
P450 metabolites/epoxyeicosatrienoic acids. H2S possesses
many common features of EDHF.
(1) Some studies have shown that the vasorelaxing effect of H2S
appears to be more potent on small-resistance mesenteric
arteries than on large aortic vascular tissues (Figure 3). It is
known that the contribution of EDHF to endothelium-
dependent vasorelaxation is much greater in smaller
arteries, including mesenteric artery and coronary artery.
(2) Zhao et al.4 has shown that the co-application of apamin
(50 nM) and charybdotoxin (50 nM) significantly weak-
ened H2S-induced relaxation of endothelium-intact rat
aortic tissues. The removal of endothelium similarly
reduced H2S effect as apamin/charybdotoxin did. The
same inhibitory effect of apamin/charybdotoxin on H2S-
induced relaxation was also observed in rat mesenteric
arteries.5 On the other hand, whether treatment of the
whole animal with apamin/charybdotoxin can affect
H2S-induced hypotension has not been reported. These
results suggest that either H2S itself is an EDHF or that
H2S releases EDHF from the endothelium.
INTERACTION OF H2S AND NO
As both H2S and NO are bioactive gas molecules, interac-
tion between these two gasotransmitters has long been
702 Kidney International (2009) 76, 700–704
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suspected. Pre-treating rat aortic tissues with 60 mM H2S
inhibited the vasorelaxant effect of sodium nitroprusside, an
NO donor. Incubation of NaHS with a range of NO donors
or NO gas in vitro was reported to form a nitrosothiol
molecule. In this way, H2S acts similar to an NO scavenger.
14
The formation of this nitrosothiol molecule inhibited the
vasorelaxant effect of NO both in vitro and in vivo. Low
concentrations of NaHS or H2S gas in solution reversed the
relaxant effects of acetylcholine and histamine on rat aortae.
NaHS also inhibited the conversion of [3H]-arginine into
[3H]-citrulline by recombinant eNOS.15 In another study on
isolated rat aortas and cultured human umbilical vein
endothelial cells, NaHS incubation reduced eNOS activity,
eNOS transcript abundance, and L-arginine transport. H2S
treatment reduced protein expression of eNOS, but not of
nNOS and iNOS. The downregulation of the vascular
L-arginine/eNOS/NO pathway was observed after intraper-
itoneal injection of NaHS (14 mmol/kg) into rats.16 In
contrast, H2S by itself had no effect on NO production from
the rat vascular SMCs, but it augmented interleukin-
b-induced NO production and this effect was associated
with increased expression of iNOS.17 Whether H2S and NO
at low concentrations have a synergistic effect on vascular
relaxation has been controversial.
To be equipped with both NO and H2S as EDRFs will
enable blood vessels with heterogeneity to relax with selective
and defined stimuli. Multiple EDRFs may help to add layers
of control or backup mechanisms should one EDRF fail
under pathological conditions. Moreover, the interaction
between these two EDRFs will either compensate the loss or
deficit, or buffer the overproduction or overaction, of one of
the two.
PERSPECTIVES AND CHALLENGES
Accumulating data on the cardiovascular effects of endogen-
ous H2S has stimulated mounting speculation that H2S might
be another EDRF or the very EDHF. Whereas the score for
the home team is up and all fans are celebrating, it is still too
early to announce the winner before hitting a home run.
Many challenges should be appropriately addressed regarding
the viewpoint of H2S being a new EDRF.
The premise that H2S is an EDRF for small resistance
arteries that NO is an EDRF for large arteries, NO-mediated
endothelium-dependent relaxation of large arteries should be
investigated in CSE knockout mice so that the relative
contribution of NO and H2S to endothelium-dependent
vasorelaxation can be deciphered.
As mentioned earlier, endogenous H2S can be generated
by another enzyme, CBS. Wang et al.18 reported the activity
of CBS as reflected by the production of cystathionine in
cultured human umbilical venous endothelial cells. However,
no attempt was taken then to detect CBS mRNA or protein in
these cells, which had been cultured for 14 days with the
addition of 100 mM L-homocysteine. This observation hints
that CBS may function as an inducible H2S-generating
enzyme in the vascular endothelial cells, which merits further
investigation. The upregulation of CBS may occur when
homocysteine level or other links of trans-sulfuration path-
way are altered. As such, not only the sulfur metabolism is
affected, endothelium-dependent production of H2S and
vasorelaxation would also be regulated under different
physiological and pathophysiological conditions.
It is of note that EDHF plays a critical role in regulating
endothelium-dependent vasorelaxation in female mice,
whereas NO and PGI2 are the predominant EDRFs in male
mice.2 Whether heterogeneity of gender affects the role of
H2S as an EDRF should be examined.
The qualification of H2S as an EDHF needs electro-
physiological recording of membrane potential changes.
H2O2 has been suggested as the EDHF.
19 In cultured rat
aortic A-10 cells, low level of NaHS decreased the production
of H2O2, ONOO
, and O2
 in the presence of homocysteine,
and improved cell viability.20 Whether the endothelium-
dependent vasorelaxant effect of H2S is mediated by altered
H2O2 production or altered redox status in endothelial cells
remains unclear.
Relative contributions of KATP channels and small/
intermediate KCa channels to the vascular effect of H2S need
to be further clarified in different vascular tissues in order to
determine whether H2S assumes the role of EDRF or EDHF
depending on vascular tissue types.
In conclusion, H2S is an accredited candidate for EDRF
and shares common features with the putative EDHF. It is
produced both in vascular endothelial cells and SMCs. Upon
muscarinic cholinergic stimulation, endothelium releases
H2S, which has two different but complementary vascular
actions. The activation of KATP channels in vascular SMCs
and of charybdotoxin/apamin sensitive KCa channels by H2S
would compound to hyperpolarize SMCs, leading to
vasorelaxation (Figure 1). Being an EDRF, H2S plays an
important role in regulating endothelium-dependent vasoac-
tive activities. Once endothelium-derived H2S is diminished,
selective resistance blood vessels will over-constrict and blood
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Figure 3 |Comparison of the vasorelaxant potencies of H2S on
endothelium-intact aorta and mesenteric arteries from rats.
Previously published data (Figure 2a from Zhao et al.4, and Figure
2a from Cheng et al.5) are pooled to synthesize and reproduce this
summary figure.
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pressure increases.9 The H2S deficiency will also likely affect
the pathogenesis progress of vascular complications of
diabetes, coronary vascular diseases, atherosclerosis, and
cardiac ischemic damage, to name a few. More extensive
and mechanistic studies in the future are expected to further
stimulate and intensify the debate on the candidacy of H2S as
a new EDRF/EDHF. No matter what the verdict of this
debate, the importance of H2S in regulating cardiovascular
function will be certainly better appreciated.
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